Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2019
At a glance
- Drugs Sacituzumab govitecan (Primary)
- Indications Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms TROPHY U-01
- Sponsors Immunomedics
- 11 Feb 2019 According to an Immunomedics media release, data will be presented at the 2019 Genitourinary Cancers Symposium.
- 23 Aug 2018 Status changed from not yet recruiting to recruiting, according to an Immunomedics media release.
- 08 Jun 2018 New trial record